116 related articles for article (PubMed ID: 32787104)
1. CDDO-imidazolide Targets Multiple Amino Acid Residues on the Nrf2 Adaptor, Keap1.
Meng X; Waddington JC; Tailor A; Lister A; Hamlett J; Berry N; Park BK; Sporn MB
J Med Chem; 2020 Sep; 63(17):9965-9976. PubMed ID: 32787104
[TBL] [Abstract][Full Text] [Related]
2. A Point Mutation at C151 of
Gatbonton-Schwager T; Yagishita Y; Joshi T; Wakabayashi N; Srinivasan H; Suzuki T; Yamamoto M; Kensler TW
Mol Pharmacol; 2023 Aug; 104(2):51-61. PubMed ID: 37188495
[TBL] [Abstract][Full Text] [Related]
3. Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis.
To C; Ringelberg CS; Royce DB; Williams CR; Risingsong R; Sporn MB; Liby KT
Carcinogenesis; 2015 Jul; 36(7):769-81. PubMed ID: 25939751
[TBL] [Abstract][Full Text] [Related]
4. Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.
Wang YY; Yang YX; Zhe H; He ZX; Zhou SF
Drug Des Devel Ther; 2014; 8():2075-88. PubMed ID: 25364233
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes.
Yates MS; Tauchi M; Katsuoka F; Flanders KC; Liby KT; Honda T; Gribble GW; Johnson DA; Johnson JA; Burton NC; Guilarte TR; Yamamoto M; Sporn MB; Kensler TW
Mol Cancer Ther; 2007 Jan; 6(1):154-62. PubMed ID: 17237276
[TBL] [Abstract][Full Text] [Related]
6. Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: biochemical, pharmacological and toxicological implications.
Walsh J; Jenkins RE; Wong M; Olayanju A; Powell H; Copple I; O'Neill PM; Goldring CE; Kitteringham NR; Park BK
J Proteomics; 2014 Aug; 108(100):171-87. PubMed ID: 24859727
[TBL] [Abstract][Full Text] [Related]
7. 2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer.
Samudio I; Konopleva M; Hail N; Shi YX; McQueen T; Hsu T; Evans R; Honda T; Gribble GW; Sporn M; Gilbert HF; Safe S; Andreeff M
J Biol Chem; 2005 Oct; 280(43):36273-82. PubMed ID: 16118208
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics of Chemically Distinct Classes of Keap1-Nrf2 Activators Identify Common and Unique Gene, Protein, and Pathway Responses In Vivo.
Wible RS; Tran QT; Fathima S; Sutter CH; Kensler TW; Sutter TR
Mol Pharmacol; 2018 Apr; 93(4):297-308. PubMed ID: 29367259
[TBL] [Abstract][Full Text] [Related]
9. Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO.
Cleasby A; Yon J; Day PJ; Richardson C; Tickle IJ; Williams PA; Callahan JF; Carr R; Concha N; Kerns JK; Qi H; Sweitzer T; Ward P; Davies TG
PLoS One; 2014; 9(6):e98896. PubMed ID: 24896564
[TBL] [Abstract][Full Text] [Related]
10. S-Glutathionylation of Keap1: a new role for glutathione S-transferase pi in neuronal protection.
Carvalho AN; Marques C; Guedes RC; Castro-Caldas M; Rodrigues E; van Horssen J; Gama MJ
FEBS Lett; 2016 May; 590(10):1455-66. PubMed ID: 27086966
[TBL] [Abstract][Full Text] [Related]
11. Design and Synthesis of Irreversible Analogues of Bardoxolone Methyl for the Identification of Pharmacologically Relevant Targets and Interaction Sites.
Wong MH; Bryan HK; Copple IM; Jenkins RE; Chiu PH; Bibby J; Berry NG; Kitteringham NR; Goldring CE; O'Neill PM; Park BK
J Med Chem; 2016 Mar; 59(6):2396-409. PubMed ID: 26908173
[TBL] [Abstract][Full Text] [Related]
12. Complete protection against aflatoxin B(1)-induced liver cancer with a triterpenoid: DNA adduct dosimetry, molecular signature, and genotoxicity threshold.
Johnson NM; Egner PA; Baxter VK; Sporn MB; Wible RS; Sutter TR; Groopman JD; Kensler TW; Roebuck BD
Cancer Prev Res (Phila); 2014 Jul; 7(7):658-65. PubMed ID: 24662598
[TBL] [Abstract][Full Text] [Related]
13. Characterization of novel small-molecule NRF2 activators: Structural and biochemical validation of stereospecific KEAP1 binding.
Huerta C; Jiang X; Trevino I; Bender CF; Ferguson DA; Probst B; Swinger KK; Stoll VS; Thomas PJ; Dulubova I; Visnick M; Wigley WC
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt A):2537-2552. PubMed ID: 27474998
[TBL] [Abstract][Full Text] [Related]
14. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling.
Liby K; Hock T; Yore MM; Suh N; Place AE; Risingsong R; Williams CR; Royce DB; Honda T; Honda Y; Gribble GW; Hill-Kapturczak N; Agarwal A; Sporn MB
Cancer Res; 2005 Jun; 65(11):4789-98. PubMed ID: 15930299
[TBL] [Abstract][Full Text] [Related]
15. Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole.
Yates MS; Kwak MK; Egner PA; Groopman JD; Bodreddigari S; Sutter TR; Baumgartner KJ; Roebuck BD; Liby KT; Yore MM; Honda T; Gribble GW; Sporn MB; Kensler TW
Cancer Res; 2006 Feb; 66(4):2488-94. PubMed ID: 16489057
[TBL] [Abstract][Full Text] [Related]
16. Growth inhibition and apoptosis of human multiple myeloma cells induced by 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid derivatives.
Rogers LJ; John T; Park J; Tucker M; Ma H; Wu Y; Rayalam S; Wang X
Anticancer Drugs; 2020 Sep; 31(8):806-818. PubMed ID: 32304407
[TBL] [Abstract][Full Text] [Related]
17. Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide.
Shin S; Wakabayashi J; Yates MS; Wakabayashi N; Dolan PM; Aja S; Liby KT; Sporn MB; Yamamoto M; Kensler TW
Eur J Pharmacol; 2009 Oct; 620(1-3):138-44. PubMed ID: 19698707
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR.
Yore MM; Kettenbach AN; Sporn MB; Gerber SA; Liby KT
PLoS One; 2011; 6(7):e22862. PubMed ID: 21818401
[TBL] [Abstract][Full Text] [Related]
19. The triterpenoid CDDO-imidazolide ameliorates mouse liver ischemia-reperfusion injury through activating the Nrf2/HO-1 pathway enhanced autophagy.
Xu D; Chen L; Chen X; Wen Y; Yu C; Yao J; Wu H; Wang X; Xia Q; Kong X
Cell Death Dis; 2017 Aug; 8(8):e2983. PubMed ID: 28796242
[TBL] [Abstract][Full Text] [Related]
20. The synthetic triterpenoid CDDO-imidazolide induces monocytic differentiation by activating the Smad and ERK signaling pathways in HL60 leukemia cells.
Ji Y; Lee HJ; Goodman C; Uskokovic M; Liby K; Sporn M; Suh N
Mol Cancer Ther; 2006 Jun; 5(6):1452-8. PubMed ID: 16818503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
